Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | SCD | O00767 | 1/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3314066 | 0.90 | MAPK14 (0.59) | MAPK14MAPK11LMNAGAAMEN1 | |
| SCHEMBL3319102 | 0.88 | MAPK14 (0.58) | MAPK14MAPK11LMNACSNK2A1GAA | |
| SCHEMBL13538872 | 0.88 | MAPK14 (0.57) | MAPK14MAPK11GAAMAPK13MAPK12 | |
| SCHEMBL3317197 | 0.88 | CSNK2A1 (0.58) | MAPK14MAPK11LMNACSNK2A1MEN1 | |
| SCHEMBL3314147 | 0.88 | MAPK14 (0.58) | MAPK14MAPK11GAAMEN1KMT2A | |
| SCHEMBL5025037 | 0.87 | MAPK14 (0.53) | MAPK14MAPK11LMNAGAAMEN1 | |
| SCHEMBL3320285 | 0.87 | CSNK2A1 (0.65) | CSNK2A1GAAMEN1KMT2AMAPT | |
| SCHEMBL3316085 | 0.87 | MAPK14 (0.55) | MAPK14LMNAGAAMEN1KMT2A | |
| SCHEMBL27636010 | 0.86 | MAPK14 (0.57) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL3317469 | 0.85 | HPGDS (0.56) | MAPK14MAPK11CSNK2A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | claimed |
| US-20100004298-A1 | P-38 INHIBITORS | DONG QING | 2010-01-07 | — | — | US | claimed |
| EP-1635824-B1 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | claimed |
| CN-1829513-A | 5-membered heterocycle-based p-38 inhibitors | NOVARTIS AG (CH) | 2006-09-06 | — | — | CN | claimed |
| EP-1635824-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | Novartis AG (CH) | 2006-03-22 | — | — | EP | claimed |
| WO-2005000298-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2005-01-06 | — | — | WO | claimed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | claimed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| US-20100004298-A1 | P-38 INHIBITORS | DONG QING | 2010-01-07 | — | — | US | disclosed |
| US-20100004298-A1 | P-38 INHIBITORS | DONG QING | 2010-01-07 | — | — | US | disclosed |
| US-20100004298-A1 | P-38 INHIBITORS | DONG QING | 2010-01-07 | — | — | US | disclosed |
| EP-1635824-B1 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| EP-1635824-B1 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| CN-1829513-A | 5-membered heterocycle-based p-38 inhibitors | NOVARTIS AG (CH) | 2006-09-06 | — | — | CN | disclosed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004298-A1 | P-38 INHIBITORS | MAPK8, MAPK1, MAP3K8 | MAPK14 21/4885MAPK11 38/4885LMNA 1125/4885 |
| US-20040254236-A1 | P-38 inhibitors | MAPK8, MAP3K8, MAPK1 | MAPK14 12/4885MAPK11 41/4885LMNA 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.